Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.
نویسندگان
چکیده
OBJECTIVE To define the extent of neuronal injury and loss in thalamic gray matter in patients with relapsing-remitting (RR) MS and to characterize how these neuronal pathologic changes are related to disease duration. METHODS The authors studied 14 patients with RRMS (Expanded Disability Status Scale score, mean 3.25, range 2.0 to 6.0) and 14 (8 men, 6 women) age-matched healthy controls. Structural MR and MRS studies were performed in a single scanning session using a 3T MR system. RESULTS N-acetylaspartate (NAA) concentrations (a measure of the apparent neuronal density) were decreased approximately 11% in the thalami of the patients with RRMS relative to controls (p < 0.05). The patients with RRMS also had an almost 25% lower mean normalized thalamic volume than controls (p < 0.005). Decreases in thalamic NAA concentration correlated strongly with thalamic volume loss for individual patients (r = 0.85, p < 0.01). Both the NAA concentration (r = -0.48, p = 0.044) and normalized thalamic volume (r = -0.60, p = 0.01) were correlated inversely with disease duration. There was a trend for a correlation between the thalamic NAA/creatine (Cr) ratio and the NAA/Cr in the frontal normal-appearing white matter (r = 0.56, p < 0.08). CONCLUSIONS The reduction of both NAA concentration and thalamic volume suggests that a neurodegenerative component may contribute to the pathology of MS even in the earlier RR stage. The trend toward a relationship between thalamic NAA/Cr and distant normal-appearing white matter changes implies that there may be a common mechanism for the white matter axonal loss and thalamic neuronal injury.
منابع مشابه
P120: Efficacy and Safety of Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disorder of central nervous system. This demyelinating disease affects more than 2.3 million people world wild. Most of patients are young adult. The most common type of MS is relapsing remitting multiple sclerosis (RRMS). However there is no cure, available modifying therapies has revolutionized the care of patients with RRMS. Interferon (IFN) be...
متن کاملIncreased Anisotropy in Subcortical Gray Matter Structures: a Neurodegeneration Marker in Multiple Sclerosis
Introduction Multiple Sclerosis (MS) is not only a chronic inflammatory disease characterized by demyelination and gliosis, but the disease also implies neurodegenerative processes. MS exhibits clinically three different forms classified as relapsing-remitting (RR) phases of inflammation followed by a secondary progressive (SP) period, or directly as a primary progressive (PP) evolution which m...
متن کاملThalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.
BACKGROUND AND PURPOSE Potential differences between primary progressive and relapsing remitting multiple sclerosis are the subject of ongoing controversial discussions. The aim of this work was to determine whether and how primary-progressive and relapsing-remitting multiple sclerosis subtypes differ regarding conventional MR imaging parameters, cerebral iron deposits, and their association wi...
متن کاملAltered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis
Background: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system and cytokines may play a role in the development of MS lesions. Objective: To determine levels of different cytokines in patients with relapsing-remitting MS (RR-MS) compared to healthy controls. Methods: Profiles of pro-inflammatory, Th1-, Th2-, and Th17-related cytokines were compared by quantitative ...
متن کاملAcute Liver Dysfunction Associated With Interferon-Beta-1a (Avonex®) Use in A Young Female Patient with Relapsing-Remitting Multiple Sclerosis (RRMS)
Background: It has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. We report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (Avonex®) intramuscular inje...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Neurology
دوره 60 12 شماره
صفحات -
تاریخ انتشار 2003